Drug Trial Radar · NCT06264440
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jul 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Feb 12, 2024
Primary completion
Jun 18, 2024
Study completion Jun 18, 2024
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the effects of a proton pump inhibitor (PPI) \[rabeprazole\] on BIIB122 pharmacokinetics (PK) after a single dose in healthy participants. The secondary objective of the study is to evaluate the safety and tolerability of BIIB122, with and without a PPI (rabeprazole), after a single dose in healthy participants.
Conditions
- Healthy Volunteer
Interventions
BIIB122Drug
Administered as specified in the treatment arm.
RabeprazoleDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Concentration (Cmax) of BIIB122Time frame: Up to Day 55
- Area Under the Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUClast) of BIIB122Time frame: Up to Day 55
- Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of BIIB122Time frame: Up to Day 55
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Development, LP
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.